/EINPresswire.com/ -- DOYLESTOWN, PA--(Marketwired - August 05, 2016) - ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the second quarter, ended June 30, 2016, will be released after the market closes on Tuesday, August 9, 2016. A conference call will be held on Wednesday August 10th, at 10:00 am EDT. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and second quarter results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at:

https://engage.vevent.com/rt/prophaselabsinc_ao~62468030 at 10:00 AM (EDT) on Wednesday, August 10, 2016.

Participants wishing to ask questions may access the live call by dialing (844) 301-0501 conference ID # 62468030. A replay of the conference call will be available for 90 days on the company website www.ProPhaseLabs.com.

About ProPhase Labs
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® cold remedy brand as well as other cold and flu relief products. Cold-EEZE® cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE® cold remedy customers include leading national chain, regional, specialty and local retail stores. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® cold remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com.

Investor Contact
Ted Karkus
Chairman and CEO
ProPhase Labs, Inc.
(215) 345-0919 x 0

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.